Published in Clin Cancer Res on July 06, 2010
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol (2012) 1.90
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med (2012) 1.89
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59
Renal cell carcinoma. BMJ (2014) 1.45
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One (2011) 1.19
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 1.11
microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One (2012) 1.11
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol (2012) 1.11
Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08
Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.08
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer (2011) 1.07
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07
Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem (2012) 1.02
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol (2011) 1.02
FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res (2014) 1.02
Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int (2013) 1.00
mTOR inhibitors in renal cell carcinoma. Therapy (2011) 1.00
Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension (2012) 0.99
Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev (2013) 0.98
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer (Auckl) (2014) 0.98
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer (2012) 0.98
Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion. PLoS One (2011) 0.97
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Transl Oncol (2013) 0.96
mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J (2013) 0.94
NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer (2014) 0.93
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
Kidney cancer. Urol Oncol (2012) 0.91
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther (2012) 0.91
Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect. PLoS One (2015) 0.91
Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma. Sarcoma (2012) 0.90
Cytotoxicity of 15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. Int J Med Sci (2012) 0.90
Targeted therapy for renal cell carcinoma: The next lap. J Carcinog (2014) 0.89
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One (2014) 0.89
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Establishment of genetically diverse patient-derived xenografts of colorectal cancer. Am J Cancer Res (2014) 0.87
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene (2012) 0.86
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One (2014) 0.86
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers (Basel) (2011) 0.85
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist (2016) 0.85
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat (2013) 0.84
Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. J Transl Med (2013) 0.84
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer (2013) 0.83
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biol Ther (2015) 0.82
A streamlined search technology for identification of synergistic drug combinations. Sci Rep (2015) 0.81
Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther (2012) 0.81
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma. Cancer J (2013) 0.81
The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol (2016) 0.80
mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS One (2014) 0.80
Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol (2015) 0.80
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res (2015) 0.80
P3Kα: a driver of tumor metastasis? Oncotarget (2010) 0.80
PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget (2015) 0.79
Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells. Cancer Med (2013) 0.79
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J Cell Biochem (2016) 0.78
Genotype directed therapy in murine mismatch repair deficient tumors. PLoS One (2013) 0.78
Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells. Evid Based Complement Alternat Med (2013) 0.77
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab (2016) 0.76
Effect of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against human Merkel cell carcinoma MKL-1 cells. Oncol Lett (2015) 0.75
Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells. J Biomed Sci (2016) 0.75
N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. J Exp Clin Cancer Res (2016) 0.75
Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo. PLoS One (2017) 0.75
Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer (2015) 0.75
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxid Med Cell Longev (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A (1998) 8.03
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem (1999) 4.62
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med (2005) 3.60
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem (2005) 3.56
Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 3.02
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet (1994) 2.65
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem (2008) 2.38
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res (2008) 2.15
eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol (2006) 1.90
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem (2005) 1.89
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.59
The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res (2006) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer (2009) 1.47
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res (2008) 1.43
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res (2007) 1.32
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res (2009) 1.13
Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol (1996) 0.99
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res (2005) 3.74
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2007) 3.00
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 2.71
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc Interv (2009) 2.30
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell (2004) 2.27
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology (2009) 2.08
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell (2013) 1.85
Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology (2010) 1.84
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Prevalence and pattern of disclosure of HIV status in HIV-infected children in Ghana. AIDS Behav (2011) 1.80
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv (2009) 1.76
Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2010) 1.76
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol (2005) 1.73
Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol (2005) 1.72
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation (2004) 1.72
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res (2002) 1.69
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract (2010) 1.62
Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. Am J Cardiol (2006) 1.59
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci U S A (2013) 1.57
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
Hidden conditional random fields. IEEE Trans Pattern Anal Mach Intell (2007) 1.48
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol (2011) 1.44
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol (2011) 1.44
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42
Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. J Invasive Cardiol (2004) 1.39
Acute angiographic and clinical results of the NIR w/SOX stent. J Invasive Cardiol (2002) 1.39
The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv (2007) 1.38
Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis (2012) 1.35
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res (2006) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol (2011) 1.34
Whole-genome plasticity among Mycobacterium avium subspecies: insights from comparative genomic hybridizations. J Bacteriol (2006) 1.33
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol (2008) 1.33
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32
p63 in prostate biology and pathology. J Cell Biochem (2008) 1.31